EMA/697757/2022

European Medicines Agency decision

P/0365/2022

of 9 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (Kerendia), (EMEA-001623-PIP03-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0365/2022

of 9 September 2022

on the acceptance of a modification of an agreed paediatric investigation plan for finerenone (Kerendia), (EMEA-001623-PIP03-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0243/2021 issued on 9 July 2021,

Having regard to the application submitted by Bayer AG on 30 May 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 22 July 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for finerenone (Kerendia), film-coated tablet, age-appropriate formulation, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0025/2015 issued on 30 January 2015, including subsequent modifications thereof.

Article 3

This decision is addressed to Bayer AG, Kaiser-Wilhelm- Allee 1, 51368 - Leverkusen, Germany.

EMA/PDCO/599548/2022
Amsterdam, 22 July 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001623-PIP03-20-M01

Scope of the application

Active substance(s):

Finerenone

Invented name:

Kerendia

Condition(s):

Treatment of heart failure

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bayer AG

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bayer AG submitted to the European Medicines Agency on 30 May 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0243/2021 issued on 9 July 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 11 July 2022.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of heart failure

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with heart failure and reduced ejection fraction

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate formulation

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age-appropriate formulation (liquid or solid) for oral and enteral use of finerenone in newborns and infants.
Non-clinical studies	**Study 2** Juvenile toxicity study of finerenone in rats.
Clinical studies	**Study 3** Randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of finerenone as add-on to standard-of-care (SOC) treatment in paediatric patients from 6 months to less than 18 years of age with heart failure (HF) due to dilated cardiomyopathy. **Study 4** Open-label extension study to evaluate the safety of finerenone as add-on to standard-of-care (SOC) treatment in paediatric patients from birth to less than 18 years of age with HF due to dilated cardiomyopathy or congenital heart disease.

Extrapolation, modelling and simulation studies	**Study 5** Physiologically based pharmacokinetic (PBPK) analysis to determine paediatric dosing for finerenone in paediatric patients with HF. **Study 6** Population pharmacokinetic/pharmacodynamic (PopPKPD) analysis to support extrapolation of efficacy of finerenone in paediatric patients with HF.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2031
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic kidney disease

Authorised indication(s):

- Treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use